FDA Archives | Page 4 of 289 | Medsearch Limited

July 13, 2021

Published by Med Search on July 13, 2021

Categories

CURE ID Moves to Automated Data Collection in Light of COVID Pandemic

By Heather Stone, MPH, FDA health science policy analyst, Center for Drug Evaluation and Research’s Office of Medical Policy In the race to find safe and effective treatments or […]

July 13, 2021

Published by Med Search on July 13, 2021

Categories

Dream Pharmacy 24/7 Enterprises Limited 2018 – 614898 – 07/01/2021

Product: Drugs Recipient: Dream Pharmacy 24/7 Enterprises Limited 2018 United States Issuing Office: Center for Drug Evaluation and Research United States DATE: July 1, 2021 WARNING […]

July 13, 2021

Published by Med Search on July 13, 2021

Categories

Guangzhou Minghui Cosmetics Co., Ltd. – 610575 – 07/06/2021

Delivery Method: VIA UPS Product: Drugs Recipient: Recipient Name Mr. Biao Chen Recipient Title General Manager Guangzhou Minghui Cosmetics Co., Ltd. No. 1, Dongchang RoadDonghua Industrial […]

July 13, 2021

Published by Med Search on July 13, 2021

Categories

UPDATED TIME INFORMATION: July 15, 2021 Meeting of the Cardiovascular and Renal Drugs Advisory Committee Meeting Announcement – 07/15/2021 – 07/15/2021

On This Page Date: July 15, 2021 Time: 9:30 AM – 5:30 PM ET UPDATED INFORMATION (as of June 28, 2021): The meeting time has changed […]

July 13, 2021

Published by Med Search on July 13, 2021

Categories

January – March 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Addyi (flibanserin) Drug hypersensitivity FDA is evaluating the need for regulatory action. Adlyxin (lixisenatide)Bydureon (exenatide)Bydureon BCise (exenatide)Byetta (exenatide)Ozempic (semaglutide)Rybelsus (semaglutide)Saxenda (liraglutide)Soliqua (insulin glargine and lixisenatide)Trulicity (dulaglutide)Victoza […]

July 13, 2021

Published by Med Search on July 13, 2021

Categories

2021_07 Test Article FT 01

Test one two three four five six seven eight. Nine ten eleven. Content current as of: 07/12/2021 Regulated Product(s) Topic(s) Health Topic(s) Law(s) & Regulation(s)

July 12, 2021

Published by Med Search on July 12, 2021

Categories

FDA approves asparaginase erwinia chrysanthemi (recombinant) for leukemia and lymphoma

On June 30, 2021, the Food and Drug Administration approved asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze, Jazz Pharmaceuticals, Inc.) as a component of a multi-agent chemotherapeutic regimen […]

July 12, 2021

Published by Med Search on July 12, 2021

Categories

FDA approves daratumumab and hyaluronidase-fihj with pomalidomide and dexamethasone for multiple myeloma

On July 9, 2021, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with pomalidomide and dexamethasone for adult […]

July 12, 2021

Published by Med Search on July 12, 2021

Categories

FDA to Discuss COVID-19’s Impact on Medical Product Operations at SBIA REdI Annual Conference

Image By: Janet Woodcock, M.D., Acting Commissioner of Food and Drugs In the face of the COVID-19 pandemic, the U.S. Food and Drug Administration has worked […]